Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 14/20 | 0.46 |
| ▸ | CA1 | P00915 | 12/20 | 0.46 |
| ▸ | CA12 | O43570 | 12/20 | 0.44 |
| ▸ | CA9 | Q16790 | 11/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 9/20 | 0.44 |
| ▸ | CA7 | P43166 | 8/20 | 0.44 |
| ▸ | CA4 | P22748 | 8/20 | 0.44 |
| ▸ | CA6 | P23280 | 7/20 | 0.44 |
| ▸ | CA5A | P35218 | 7/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 7/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12988457 | 0.81 | CA2 (0.46) | CA2CA1CA12CA9CA14 | |
| SCHEMBL12989492 | 0.81 | CA2 (0.46) | CA2CA1CA12CA9CA14 | |
| SCHEMBL28774202 | 0.79 | ALDH1A1 (0.38) | ALDH1A1MAPTPKMRAB9ATDP1 | |
| SCHEMBL30204094 | 0.79 | ALDH1A1 (0.38) | ALDH1A1MAPTPKMRAB9ATDP1 | |
| SCHEMBL12988642 | 0.77 | CA2 (0.45) | CA2CA1CA12CA9CA14 | |
| SCHEMBL5336260 | 0.74 | CA2 (0.46) | CA2CA1CA12CA9CA14 | |
| SCHEMBL15202208 | 0.74 | CA2 (0.42) | CA2CA1CA12CA9CA14 | |
| SCHEMBL2005036 | 0.73 | CA2 (0.74) | CA2CA1CA12CA9CA7 | |
| SCHEMBL2549992 | 0.73 | PKM (0.61) | CA2CA12CA9HTTMEN1 | |
| SCHEMBL12989734 | 0.71 | CA12 (0.56) | CA2CA12CA9LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1888517-A1 | NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR | AstraZeneca AB (SE) | 2008-02-20 | — | — | EP | claimed |
| WO-2006126939-A1 | NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | claimed |
| US-8877757-B2 | Pyrazine derivatives and use as PI3K inhibitors | MERCK SERONO SA (CH) | 2014-11-04 | — | — | US | disclosed |
| WO-2013027168-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | PFIZER INC. (US) | 2013-02-28 | — | — | WO | disclosed |
| US-20110319410-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | MERCK SERONO SA (CH) | 2011-12-29 | — | — | US | disclosed |
| US-20110312960-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | MERCK SERONO SA (CH) | 2011-12-22 | — | — | US | disclosed |
| US-8071597-B2 | Pyrazine compounds and uses as PI3K inhibitors | MERCK SERONO SA (CH) | 2011-12-06 | — | — | US | disclosed |
| EP-2150255-A1 | QUINOXALINE DERIVATIVES AS P13 KINASE INHIBITORS | Smithkline Beecham Corporation (US) | 2010-02-10 | — | — | EP | disclosed |
| US-20090082356-A1 | Pyrazine Derivatives and Use as P13k Inhibitors | MERCK SERONO SA (CH) | 2009-03-26 | — | — | US | disclosed |
| WO-2008141065-A1 | QUINOXALINE DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082356-A1 | Pyrazine Derivatives and Use as P13k Inhibitors | PI4KA, PIP5K1B, PDPK1 | CA2 4494/4885CA1 4591/4885CA12 4791/4885 |
| US-20110312960-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | PIK3R5, PIK3CD, PIK3CA | CA2 4646/4885CA1 4761/4885CA12 4747/4885 |
| US-20110319410-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | PIK3R5, PIK3CD, PIK3CA | CA2 4646/4885CA1 4761/4885CA12 4747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.